Figure 1.
In vivo selection in dog G179 after multiple cycles of O6BG and temozolomide. (A-B) Flow cytometric analysis. (A) Percent EGFP-positive granulocytes (○) and lymphocytes (▪) from peripheral blood. (B) Percent EGFP-positive red blood cells (○) and platelets (▪) from peripheral blood. (C) Percent EGFP-positive CD34+ cells from bone marrow (○). (D) Quantification of provirus in leukocytes from peripheral blood by Taqman-PCR. Arrows indicate the treatment cycles. O6BG was used at a fixed dose of 5 mg/kg with a maximal dose of 50 mg per administration. The doses of temozolomide were (1) 50 mg/m2, (2) 100 mg/m2, (3) 100 mg/m2, (4) 200 mg/m2, (5) 300 mg/m2, (6) 400 mg/m2, (7) 500 mg/m2, (8) 600 mg/m2, and (9) 700 mg/m2.
